Lamassu BioTech
Share
Accelerating treatment, means saving more lives.
10/01/2026
October is Breast Cancer Awareness Month, a time to raise awareness, show support, and take action in the fight against breast cancer. Whether you're a survivor or someone battling breast cancer diagnosis, our team at Lamassu Biotech honors and supports you.
09/30/2026
Nearly 2 million Americans receive a cancer diagnosis each year. But government agencies and researchers have traditionally—and understandably—focused on more common cancers that affect the largest numbers of patients. This can leave people battling a rare cancer diagnoses with few treatment options. At Lamassu Biotech our novel genetically targeted therapy SA53, works by triggering the body’s natural defense mechanism, p53, which inhibits or blocks a protein called MDM2. The p53 pathway is one of the most important natural defense mechanisms your body has against cancer. Learn more at LamassuBiotech.com/sa53/.
𝐀 𝐧𝐞𝐰 𝐜𝐚𝐧𝐜𝐞𝐫-𝐟𝐢𝐠𝐡𝐭𝐢𝐧𝐠 𝐭𝐞𝐚𝐦 𝐢𝐬 𝐨𝐧 𝐭𝐡𝐞 𝐬𝐜𝐞𝐧𝐞. The p53 pathway is one of the most important natural defense mechanisms your body has against cancer.
Known as the “Guardian of the Genome,” the body's p53 protein is a crucial tumor suppressor gene commonly mutated in human cancers. Lamassu BioTech's innovative, genetically targeted treatment, SA53, is a novel therapeutic that works by triggering p53, which inhibits or blocks the MDM2 protein.
Lamassu’s ongoing human clinical trial focuses on achieving a safe dosage for future trials, understanding pharmacokinetic profiles, and assessing early signs of effectiveness in treating soft tissue sarcomas and solid tumors with wild type p53.
Each year, World Cancer Research Day brings together patients, researchers, healthcare professionals, funders, policymakers and communities to recognize the impact of cancer research and the power of collaboration. At Lamassu Biotech, our team of dedicated physicians, engineers, and translational scientists are driven by a passion to treat patients like family. We take a patient-centric approach to research and drug development that focuses on making advancements that address unmet needs with novel and targeted strategies, ensuring greater efficiency and shorter approval timeframes. With decades of experience developing leading medical therapies, Lamassu has proven not only the transformative power of science, but also how hope leads to healing.
09/18/2026
September is Childhood Cancer Awareness Month. It shines a light on children with cancer and the challenges they face each and every day. While the overall outlook for children and adolescents with cancer has improved greatly over the last half-century, an estimated 1,600 kids in the U.S. lose their battle with cancer each year, making it the leading cause of death by disease among children. At Lamassu Biotech, we work every day to bring hope and healing to these young people.
07/09/2026
During , hosted by the Liposarcoma Support Network, Lamassu Biotech CSO Dr. Greg Palmer will provide attendees with an update about ongoing Phase 1/2 trial of SA-53, a targeted therapy that activates p53, the "Guardian of Genome" to kill cancer tumors. The treatment is currently being investigated in adult patients with sarcoma, who currently have limited therapeutic options, and is already showing favorable phase 1 safety data.
07/07/2026
July is Sarcoma Awareness Month. Lamassu Biotech's pioneering therapy, SA-53, has the potential to transform the way we treat cancer. This groundbreaking treatment is being investigated in adult patients with sarcoma and other solid tumors who possess the p53 wild-type gene and who currently have limited therapeutic options. It’s just one of the ways we’re bringing hope and healing to those who need it most. Learn more at www.LamassuBiotech.com.
Has your dog stopped eating? Lethargic? Appears to be in pain? Canine acute pancreatitis is a life-threatening condition that effects thousands of dogs each year, especially schnauzers, terriers, and cocker spaniels. Right now, there is no effective treatment. But if your dog is suffering from acute pancreatitis, they may be eligible to participate in a groundbreaking clinical trial being administered by veterinarians at The Ohio State University College of Veterinary Medicine. Learn more and sign up at www.LamassuPets.com.
04/24/2026
Be sure to catch Lamassu BioTech CEO Dr. Gabi Hanna's panel discussion on the integration of biotechnology and digital platforms to create smarter, more personalized therapies and diagnostics during C3 Summit International's US Sunnyvale Davos of Healthcare Summit on Monday, April 27. Interested in connecting with Dr. Hanna during the summit? Email [email protected].
04/23/2026
With more than three decades of experience working in the field of medical oncology and radiation oncology, the 24th Commissioner of Food and Drugs, Dr. Stephen Hahn, has established himself as a national leader in healthcare and a distinguished physician. As the newest member of Lamassu Biotech’s Board of Directors, his expertise will assist our team of physician-scientists as we advance our genetically targeted therapy, SA53, which could be transformative in treating upwards of 50% of all cancer cases including those that currently lack effective treatments.
Full announcement 🔗 in the comments.
Click here to claim your Sponsored Listing.